A state-of-the-art polygenic score for idiopathic Parkinson’s disease: benchmarking methods and impact on genetic PD carriers

Abstract Genetic causes are identified in up to 15% of Parkinson’s disease (PD) patients; the remaining idiopathic PD (iPD) patients are attributed to polygenic risk, environmental and lifestyle factors, and interactions thereof. We applied five advanced polygenic score (PGS) tools to data from 1762 iPD patients and 4227 healthy controls of European ancestry. 5-fold cross-validation revealed a significant boost in the discriminative power of modern Bayesian methods over simpler approaches, leading to the development of a novel iPD-PGS. This score demonstrated significantly improved performance compared to existing scores, achieving an area under the curve (AUC) of 0.680 (95% confidence interval (-CI):[0.665, 0.695]). External validation confirmed its robustness. Early-onset iPD patients exhibited higher PGS values than late-onset iPD patients and healthy controls, indicating increased polygenetic burden. Applying our novel iPD-PGS to carriers of heterozygous PRKN variants and GBA1 coding risk variants suggested that penetrance in these groups is partly explained by the same polygenic alterations as observed mitigating iPD. GBA1 showed a trend toward higher discriminative potential than PRKN ( GBA1 : AUC = 0.639, 95%-CI:[0.590, 0.687]; PRKN : AUC = 0.594, 95%-CI:[0.501, 0.687]), though confidence intervals overlapped. Our study highlights the potential of advanced PGSs in PD research, particularly in identifying high-risk individuals and modifying risk in rare-variant carriers.

Authors

Institutions

Publication Details

Journal
npj Parkinson s Disease
Published
2026-11-14
DOI
https://doi.org/10.1038/s41531-026-01459-9
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A state-of-the-art polygenic score for idiopathic Parkinson’s disease: benchmarking methods and impact on genetic PD carriers

Daniela Berg, Katja Lohmann, Michael Wittig, Wolfgang Lieb et al.
1 links
npj Parkinson s Disease
Parkinson's Disease Mechanisms and Treatments
article

A state-of-the-art polygenic score for idiopathic Parkinson’s disease: benchmarking methods and impact on genetic PD carriers

Daniela Berg, Katja Lohmann, Michael Wittig, Wolfgang Lieb, Ulrike M. Krämer, Sebastian Sendel, Claudia Trenkwalder, Ana Westenberger, Inke Regina König, Christine Klein, Alexander Balck, Björn‐Hergen Laabs, Miriam Neis, Amke Caliebe, Andrew A. Hicks, Lara Mariah Lange, Dheeraj Reddy Bobbili, Max Borsche, Patrick May, Zied Landoulsi, Emadeldin Hassanin, Eva Schaeffer, Peter Paul Pramstaller, Tatiana Usnich, André Franke, Norbert Brüggemann, Meike Kasten, Brit Mollenhauer, Jannik Prasuhn, Eva‐Juliane Vollstedt, Henrike Hanßen, Gregor Kuhlenbäumer, Rejko Krüger
article en

Abstract

Abstract Genetic causes are identified in up to 15% of Parkinson’s disease (PD) patients; the remaining idiopathic PD (iPD) patients are attributed to polygenic risk, environmental and lifestyle factors, and interactions thereof. We applied five advanced polygenic score (PGS) tools to data from 1762 iPD patients and 4227 healthy controls of European ancestry. 5-fold cross-validation revealed a significant boost in the discriminative power of modern Bayesian methods over simpler approaches, leading to the development of a novel iPD-PGS. This score demonstrated significantly improved performance compared to existing scores, achieving an area under the curve (AUC) of 0.680 (95% confidence interval (-CI):[0.665, 0.695]). External validation confirmed its robustness. Early-onset iPD patients exhibited higher PGS values than late-onset iPD patients and healthy controls, indicating increased polygenetic burden. Applying our novel iPD-PGS to carriers of heterozygous PRKN variants and GBA1 coding risk variants suggested that penetrance in these groups is partly explained by the same polygenic alterations as observed mitigating iPD. GBA1 showed a trend toward higher discriminative potential than PRKN ( GBA1 : AUC = 0.639, 95%-CI:[0.590, 0.687]; PRKN : AUC = 0.594, 95%-CI:[0.501, 0.687]), though confidence intervals overlapped. Our study highlights the potential of advanced PGSs in PD research, particularly in identifying high-risk individuals and modifying risk in rare-variant carriers.

npj Parkinson s Disease
Eurac Research (IT), University of Luxembourg (LU), Christian-Albrechts-Universität zu Kiel (DE), University Hospital Schleswig-Holstein (DE), Institute for Biomedicine (IT), Paracelsus Elena Klinik Kassel (DE), Luxembourg Centre for Systems Biomedicine (LU), University of Tübingen (DE), University of Lübeck (DE)
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon